WO2001064164A3 - Nanocapsule encapsulation system and method - Google Patents

Nanocapsule encapsulation system and method Download PDF

Info

Publication number
WO2001064164A3
WO2001064164A3 PCT/US2001/006455 US0106455W WO0164164A3 WO 2001064164 A3 WO2001064164 A3 WO 2001064164A3 US 0106455 W US0106455 W US 0106455W WO 0164164 A3 WO0164164 A3 WO 0164164A3
Authority
WO
WIPO (PCT)
Prior art keywords
nanocapsules
surfactant
nanocapsule
hydrophilic polymer
encapsulation system
Prior art date
Application number
PCT/US2001/006455
Other languages
French (fr)
Other versions
WO2001064164A2 (en
Inventor
Gretchen M Unger
Original Assignee
Genesegues Inc
Gretchen M Unger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genesegues Inc, Gretchen M Unger filed Critical Genesegues Inc
Priority to AU2001247244A priority Critical patent/AU2001247244B2/en
Priority to EP01920161A priority patent/EP1267946A4/en
Priority to AU4724401A priority patent/AU4724401A/en
Priority to CA2400172A priority patent/CA2400172C/en
Priority to JP2001563063A priority patent/JP4751556B2/en
Priority to MXPA02008361A priority patent/MXPA02008361A/en
Publication of WO2001064164A2 publication Critical patent/WO2001064164A2/en
Publication of WO2001064164A3 publication Critical patent/WO2001064164A3/en
Priority to HK03101090.4A priority patent/HK1048772A1/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B01J13/06—Making microcapsules or microballoons by phase separation
    • B01J13/08—Simple coacervation, i.e. addition of highly hydrophilic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/795—Composed of biological material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/84—Manufacture, treatment, or detection of nanostructure
    • Y10S977/895—Manufacture, treatment, or detection of nanostructure having step or means utilizing chemical property
    • Y10S977/896—Chemical synthesis, e.g. chemical bonding or breaking
    • Y10S977/897—Polymerization
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/92—Detection of biochemical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Dispersion Chemistry (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention generally relates to nanocapsules and methods of preparing these nanocapsules. The present invention includes a method of forming a surfactant micelle and dispersing the surfactant micelle into an aqueous composition having a hydrophilic polymer to form a stabilized dispersion of surfactant micelles. The method further includes mechanically forming droplets of the stabilized dispersion of surfactant micelles, precipitating the hydrophilic polymer to form precipitated nanocapsules, incubating the nanocapsules to reduce a diameter of the nanocapsules, and filtering or centrifuging the nanocapsules.
PCT/US2001/006455 2000-02-28 2001-02-28 Nanocapsule encapsulation system and method WO2001064164A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2001247244A AU2001247244B2 (en) 2000-02-28 2001-02-28 Nanocapsule encapsulation system and method
EP01920161A EP1267946A4 (en) 2000-02-28 2001-02-28 Nanocapsule encapsulation system and method
AU4724401A AU4724401A (en) 2000-02-28 2001-02-28 Nanocapsule encapsulation system and method
CA2400172A CA2400172C (en) 2000-02-28 2001-02-28 Nanocapsule encapsulation system and method
JP2001563063A JP4751556B2 (en) 2000-02-28 2001-02-28 Nanocapsule encapsulation system and method
MXPA02008361A MXPA02008361A (en) 2000-02-28 2001-02-28 Nanocapsule encapsulation system and method.
HK03101090.4A HK1048772A1 (en) 2000-02-28 2003-02-14 Nanocapsule encapsulation system and method

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18528200P 2000-02-28 2000-02-28
US60/185,282 2000-02-28

Publications (2)

Publication Number Publication Date
WO2001064164A2 WO2001064164A2 (en) 2001-09-07
WO2001064164A3 true WO2001064164A3 (en) 2001-12-20

Family

ID=22680346

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/006455 WO2001064164A2 (en) 2000-02-28 2001-02-28 Nanocapsule encapsulation system and method

Country Status (9)

Country Link
US (2) US6632671B2 (en)
EP (1) EP1267946A4 (en)
JP (1) JP4751556B2 (en)
CN (1) CN1406140A (en)
AU (2) AU4724401A (en)
CA (1) CA2400172C (en)
HK (1) HK1048772A1 (en)
MX (1) MXPA02008361A (en)
WO (1) WO2001064164A2 (en)

Families Citing this family (154)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6433154B1 (en) 1997-06-12 2002-08-13 Bristol-Myers Squibb Company Functional receptor/kinase chimera in yeast cells
US20030206958A1 (en) * 2000-12-22 2003-11-06 Cattaneo Maurizio V. Chitosan biopolymer for the topical delivery of active agents
CA2400172C (en) * 2000-02-28 2010-04-20 Genesegues, Inc. Nanocapsule encapsulation system and method
JP2004500975A (en) 2000-05-16 2004-01-15 リージェンツ　オブ　ザ　ユニバーシティ　オブ　ミネソタ High throughput particle generator and particle generation method using multiple nozzle spray operations
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US20030096013A1 (en) * 2000-12-22 2003-05-22 Jane Werling Preparation of submicron sized particles with polymorph control
US7247338B2 (en) * 2001-05-16 2007-07-24 Regents Of The University Of Minnesota Coating medical devices
BR0211028A (en) * 2001-06-22 2004-06-15 Pfizer Prod Inc Aqueous solution, method for forming drug and polymer combinations, pharmaceutical compositions, method for forming a pharmaceutical composition and product
US7081489B2 (en) * 2001-08-09 2006-07-25 Florida State University Research Foundation Polymeric encapsulation of nanoparticles
CA2461349C (en) 2001-09-26 2011-11-29 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US7491810B2 (en) * 2001-11-30 2009-02-17 U.S. Department Of Veterans Affairs Transgenic screen and method for screening modulators of brain-derived neurotrophic factor (BDNF) production
US7615676B2 (en) * 2001-11-30 2009-11-10 U.S. Department Of Veterans Affairs Transgenic screen and method for screening modulators of brain-derived neurotrophic factor (BDNF) production
US20040038303A1 (en) * 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
US7053034B2 (en) * 2002-04-10 2006-05-30 Salvona, Llc Targeted controlled delivery compositions activated by changes in pH or salt concentration
DE10236064A1 (en) * 2002-08-07 2004-02-19 Beiersdorf Ag Foaming sunscreen preparations
US6989196B2 (en) * 2002-10-02 2006-01-24 Florida State University Research Foundation Microencapsulation of magnetic material using heat stabilization
US7605249B2 (en) 2002-11-26 2009-10-20 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
US7829694B2 (en) 2002-11-26 2010-11-09 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
US20060018882A1 (en) * 2004-06-21 2006-01-26 Kaemmerer William F Medical devices and methods for delivering compositions to cells
US7618948B2 (en) 2002-11-26 2009-11-17 Medtronic, Inc. Devices, systems and methods for improving and/or cognitive function through brain delivery of siRNA
US7732591B2 (en) * 2003-11-25 2010-06-08 Medtronic, Inc. Compositions, devices and methods for treatment of huntington's disease through intracranial delivery of sirna
US7994149B2 (en) 2003-02-03 2011-08-09 Medtronic, Inc. Method for treatment of Huntington's disease through intracranial delivery of sirna
AU2004249172A1 (en) * 2003-06-24 2004-12-29 Baxter International Inc. Specific delivery of drugs to the brain
US8986736B2 (en) * 2003-06-24 2015-03-24 Baxter International Inc. Method for delivering particulate drugs to tissues
BRPI0412734A (en) * 2003-07-17 2006-09-26 Tibotec Pharm Ltd process for preparing particles containing an antiviral
WO2005041865A2 (en) * 2003-10-21 2005-05-12 Igf Oncology, Llc Compounds and method for treating cancer
US9011880B2 (en) * 2003-10-21 2015-04-21 Igf Oncology, Llc Compounds and methods for treating cancer
WO2005072292A2 (en) * 2004-01-24 2005-08-11 Hugh Mctavish Methods for enhancing radiation therapy
WO2005072706A2 (en) * 2004-01-29 2005-08-11 Baxter International Inc. Nanosuspensions of anti-retroviral agents for increased central nervous system delivery
KR20050081092A (en) * 2004-02-12 2005-08-18 한국과학기술연구원 Composition and formulation of colloidal system comprising biocompatible aqueous-soluble polymer, and preparation method thereof
US7354980B1 (en) 2004-03-12 2008-04-08 Key Medical Technologies, Inc. High refractive index polymers for ophthalmic applications
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
US20050281886A1 (en) * 2004-05-06 2005-12-22 Ivrea Pharmaceuticals, Inc. Particles for the delivery of active agents
US7842281B2 (en) * 2004-05-10 2010-11-30 The Florida State University Research Foundation Magnetic particle composition for therapeutic hyperthermia
AU2005255039A1 (en) * 2004-06-15 2005-12-29 Baxter Healthcare S.A. Ex-vivo application of solid microparticulate therapeutic agents
EP1812082B1 (en) 2004-10-21 2013-08-14 IGF Oncology, LLC Toxins and radionuclides coupled to IGF-1 receptor ligands for the treatment of cancer
US7446157B2 (en) * 2004-12-07 2008-11-04 Key Medical Technologies, Inc. Nanohybrid polymers for ophthalmic applications
WO2006065724A2 (en) * 2004-12-14 2006-06-22 Regents Of The University Of Minnesota Casein kinase 2 antisense therapy
US8871272B2 (en) 2005-02-14 2014-10-28 Australian Nuclear Science & Technology Organisation Layered nanoparticles
US20060222692A1 (en) * 2005-03-31 2006-10-05 Fairfield Clinical Trials Llc Method and compositions for transdermal administration of antimicrobial medications
US7902352B2 (en) * 2005-05-06 2011-03-08 Medtronic, Inc. Isolated nucleic acid duplex for reducing huntington gene expression
WO2006121960A2 (en) * 2005-05-06 2006-11-16 Medtronic, Inc. Methods and sequences to suppress primate huntington gene expression
KR20080047509A (en) * 2005-05-23 2008-05-29 엘란 파마 인터내셔널 리미티드 Nanoparticulate and controlled release compositions comprising a platelet aggregation inhibitor
US9133517B2 (en) * 2005-06-28 2015-09-15 Medtronics, Inc. Methods and sequences to preferentially suppress expression of mutated huntingtin
US20080280843A1 (en) * 2006-05-24 2008-11-13 Van Bilsen Paul Methods and kits for linking polymorphic sequences to expanded repeat mutations
JP5093903B2 (en) 2005-10-14 2012-12-12 バイブ ナノ， インコーポレイテッド Composite nanoparticles, nanoparticles and method for producing the same
CN1962155A (en) * 2005-11-10 2007-05-16 鸿富锦精密工业（深圳）有限公司 CO2 laser welding apparatus
US7741396B2 (en) * 2005-11-23 2010-06-22 General Electric Company Composites having tunable dielectric constants, methods of manufacture thereof, and articles comprising the same
EP1960001A2 (en) 2005-12-08 2008-08-27 Koninklijke Philips Electronics N.V. System and method for monitoring in vivo drug release using overhauser-enhanced nmr
US9108217B2 (en) 2006-01-31 2015-08-18 Nanocopoeia, Inc. Nanoparticle coating of surfaces
CA2641117C (en) 2006-01-31 2018-01-02 Nanocopoeia, Inc. Nanoparticle coating of surfaces
WO2007089881A2 (en) 2006-01-31 2007-08-09 Regents Of The University Of Minnesota Electrospray coating of objects
US20100119827A1 (en) * 2006-04-25 2010-05-13 Research Foundation Of The City University Of New York Polymer submicron particle preparation by surfactant-mediated precipitation
US9273356B2 (en) 2006-05-24 2016-03-01 Medtronic, Inc. Methods and kits for linking polymorphic sequences to expanded repeat mutations
US20110135742A1 (en) * 2006-06-20 2011-06-09 The Regents Of The University Of California Controlled release encapsulated anti-bacterial and anti-inflammatory nanoparticles
US20080039415A1 (en) * 2006-08-11 2008-02-14 Gregory Robert Stewart Retrograde transport of sirna and therapeutic uses to treat neurologic disorders
WO2008021666A2 (en) * 2006-08-18 2008-02-21 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
US9375440B2 (en) * 2006-11-03 2016-06-28 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
US8324367B2 (en) 2006-11-03 2012-12-04 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
US7819842B2 (en) * 2006-11-21 2010-10-26 Medtronic, Inc. Chronically implantable guide tube for repeated intermittent delivery of materials or fluids to targeted tissue sites
US7988668B2 (en) * 2006-11-21 2011-08-02 Medtronic, Inc. Microsyringe for pre-packaged delivery of pharmaceuticals
US9040816B2 (en) 2006-12-08 2015-05-26 Nanocopoeia, Inc. Methods and apparatus for forming photovoltaic cells using electrospray
US20080171906A1 (en) * 2007-01-16 2008-07-17 Everaerts Frank J L Tissue performance via hydrolysis and cross-linking
EP1955695A1 (en) * 2007-02-06 2008-08-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nanocapsules of lipophilic complexes of nucleic acids
US20080193766A1 (en) * 2007-02-13 2008-08-14 Northern Nanotechnologies Control of Transport to and from Nanoparticle Surfaces
EP2152241A4 (en) * 2007-04-30 2012-11-14 Agency Science Tech & Res Method of delivering a protein into a cell
US8703204B2 (en) 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
US8309129B2 (en) 2007-05-03 2012-11-13 Bend Research, Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
EP2162120B1 (en) 2007-06-04 2016-05-04 Bend Research, Inc Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
WO2008157514A2 (en) * 2007-06-14 2008-12-24 Genesegues, Inc. Metal ion-treated biocompatible polymers useful for nanoparticles
US20090042825A1 (en) * 2007-08-06 2009-02-12 Majed Matar Composition, method of preparation & application of concentrated formulations of condensed nucleic acids with a cationic lipopolymer
US9144546B2 (en) 2007-08-06 2015-09-29 Clsn Laboratories, Inc. Nucleic acid-lipopolymer compositions
US7973019B1 (en) 2007-10-03 2011-07-05 Alcon Research, Ltd. Transferrin/transferrin receptor-mediated siRNA delivery
US20090131358A1 (en) 2007-11-15 2009-05-21 Alcon Research, Ltd. LOW DENSITY LIPOPROTEIN RECEPTOR-MEDIATED siRNA DELIVERY
WO2009073586A1 (en) * 2007-11-30 2009-06-11 Chemi Nutra, Llc. Methods using phosphatidylserine, lysophosphatidylserine, and/or salts thereof to increase testosterone levels
WO2009073216A1 (en) 2007-12-06 2009-06-11 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an amine-functionalized methacrylate copolymer
EP2231169B1 (en) 2007-12-06 2016-05-04 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
JP2011508281A (en) * 2007-12-28 2011-03-10 ダウ グローバル テクノロジーズ インコーポレイティド Phase compensation film containing polymer nanoparticles absorbing liquid crystal material
KR20100112592A (en) * 2007-12-28 2010-10-19 다우 글로벌 테크놀로지스 인크. Small scale functional materials
WO2009101612A2 (en) * 2008-02-11 2009-08-20 Technion Research And Development Foundation Ltd. Beta-casein assemblies for enrichment of food and beverages and methods of preparation thereof
US20110045092A1 (en) * 2008-02-11 2011-02-24 Livney Yoav D Casein particles encapsulating therapeutically active agents and uses thereof
US8871276B2 (en) 2008-02-11 2014-10-28 Technion Research And Development Foundation Ltd. Beta-casein assemblies for mucosal delivery of therapeutic bioactive agents
US8865223B2 (en) * 2008-02-11 2014-10-21 Technion Research And Development Foundation Ltd. Beta-casein assemblies for mucosal delivery of therapeutic bioactive agents
EP2249817B8 (en) * 2008-02-18 2012-03-21 Csir Nanoparticle carriers for drug administration and process for producing same
WO2009111638A1 (en) 2008-03-05 2009-09-11 Baxter International Inc. Compositions and methods for drug delivery
IE20080211A1 (en) 2008-03-20 2009-11-25 Nat Univ Ireland Biodegradable nanoshells for delivery of therapeutic and/or imaging molecules
WO2009126742A2 (en) * 2008-04-08 2009-10-15 Appian Labs, Llc Enzyme mediated delivery system
US20100010102A1 (en) * 2008-07-09 2010-01-14 Board Of Regents, The University Of Texas System Triggered release of drugs from polymer particles
WO2010102065A1 (en) 2009-03-05 2010-09-10 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives
US10952965B2 (en) * 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
AU2010254551B2 (en) 2009-05-27 2016-10-20 Selecta Biosciences, Inc. Immunomodulatory agent-polymeric compounds
WO2011017382A2 (en) * 2009-08-03 2011-02-10 The Regents Of The University Of California Nanofibers and morphology shifting micelles
US8470304B2 (en) 2009-08-04 2013-06-25 Avidas Pharmaceuticals Llc Therapeutic vitamin D sun-protecting formulations and methods for their use
CN107715118A (en) 2009-08-26 2018-02-23 西莱克塔生物科技公司 The composition of inducing T cell auxiliary
US20120076735A1 (en) * 2010-03-24 2012-03-29 Genesegues, Inc. Nanoparticles for Extravascular Administration
US9650244B2 (en) 2010-08-25 2017-05-16 Genesegues, Inc. Topical vaccination via DNA microparticles
NO2575876T3 (en) 2010-05-26 2018-05-05
US8815294B2 (en) 2010-09-03 2014-08-26 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives and a carrier material
US8709487B1 (en) 2011-04-25 2014-04-29 The United States Of America As Represented By The Secretary Of The Army Nanoparticle entrapment of materials
KR20230006042A (en) 2011-04-29 2023-01-10 셀렉타 바이오사이언시즈, 인크. Tolerogenic synthetic nanocarriers to reduce antibody responses
US9060938B2 (en) 2011-05-10 2015-06-23 Bend Research, Inc. Pharmaceutical compositions of active agents and cationic dextran polymer derivatives
WO2012161677A1 (en) 2011-05-20 2012-11-29 Alcon Research, Ltd. TRANSFERRIN/TRANSFERRIN RECEPTOR-MEDIATED siRNA DELIVERY
CA2843274A1 (en) 2011-07-29 2013-02-07 Selecta Biosciences, Inc. Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses
KR20140051357A (en) * 2011-08-26 2014-04-30 애로우헤드 리서치 코오포레이션 Poly(vinyl ester) polymers for in vivo nucleic acid delivery
US9474715B2 (en) * 2011-11-30 2016-10-25 Andreas Voigt Polymeric drug-delivery material, method for manufacturing thereof and method for delivery of a drug-delivery composition
US10485861B2 (en) 2013-03-14 2019-11-26 President And Fellows Of Harvard College Nanoparticle-based compositions
CN110841067A (en) 2013-05-03 2020-02-28 西莱克塔生物科技公司 Tolerogenic synthetic nanocarriers and therapeutic macromolecules for reduced or enhanced pharmacodynamic effects
EP3003306B1 (en) 2013-06-04 2020-08-26 Selecta Biosciences, Inc. Repeated administration of non-immunosupressive antigen specific immunotherapeutics
CN103550155A (en) * 2013-11-08 2014-02-05 江南大学 Method of restraining production of lysophosphatide in lecithin/non-ionic surfactant mixed micelles
EP3094339B1 (en) 2014-01-12 2019-12-11 IGF Oncology, LLC Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof
AU2015279738A1 (en) 2014-06-25 2016-12-22 Selecta Biosciences, Inc. Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors
SG10201902499VA (en) * 2014-09-03 2019-04-29 Genesegues Inc Therapeutic nanoparticles and related compositions, methods and systems
CN107073091A (en) 2014-09-07 2017-08-18 西莱克塔生物科技公司 Method and composition for weakening the antiviral transfer vector immune response of exon skipping
US20160128987A1 (en) 2014-11-05 2016-05-12 Selecta Biosciences, Inc. Methods and compositions related to synthetic nanocarriers with rapamycin in a stable, super-saturated state
KR101663775B1 (en) * 2014-11-13 2016-10-07 주식회사 엘지생활건강 Composition for stabilizing polyphenolic effective ingredient
AR106018A1 (en) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
EP3340982B1 (en) 2015-08-26 2021-12-15 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
JP7417354B2 (en) 2016-03-11 2024-01-18 セレクタ バイオサイエンシーズ インコーポレーテッド PEGylated uricase formulation and dosage
MX2018016046A (en) 2016-06-27 2019-05-02 Achillion Pharmaceuticals Inc Quinazoline and indole compounds to treat medical disorders.
US20180085319A1 (en) 2016-09-27 2018-03-29 Takashi Kei Kishimoto Methods and compositions for treating cancer
EP3541391A4 (en) 2016-11-17 2020-06-17 The University of North Carolina at Chapel Hill Alkyl pyrrolopyrimidine analogs and methods of making and using same
KR20240015743A (en) 2017-01-07 2024-02-05 셀렉타 바이오사이언시즈, 인크. Patterned dosing of immunosuppressants coupled to synthetic nanocarriers
BR112019018748A2 (en) 2017-03-11 2020-04-07 Selecta Biosciences Inc methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
KR20200000438A (en) 2017-05-21 2020-01-02 아이쥐에프 온콜로지, 엘엘씨 Insulin-like growth factor-chemotherapy conjugate for treating myelodysplastic syndrome
US20190142974A1 (en) 2017-10-13 2019-05-16 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
US20190151470A1 (en) * 2018-01-21 2019-05-23 RoverMed BioSciences, LLC Nanoparticles comprising protein-polynucleotide complexes and for delivering protein based complexes
CN108414393A (en) * 2018-06-13 2018-08-17 安徽中医药大学 A method of measuring entrapment efficiency of liposome
US20200038463A1 (en) 2018-07-16 2020-02-06 Selecta Biosciences, Inc. Methods and compositions of mma constructs and vectors
CN112771070A (en) 2018-07-16 2021-05-07 西莱克塔生物科技公司 Methods and compositions of OTC constructs and vectors
JP2021535112A (en) 2018-08-20 2021-12-16 アキリオン ファーマシューティカルズ，インコーポレーテッド Pharmaceutical compounds for the treatment of medical disorders of complement D factor
EP3866773A4 (en) 2018-10-16 2022-10-26 Georgia State University Research Foundation, Inc. Carbon monoxide prodrugs for the treatment of medical disorders
US20200360453A1 (en) 2019-04-28 2020-11-19 Selecta Biosciences, Inc. Methods for treatment of subjects with preexisting immunity to viral transfer vectors
CN114206396A (en) 2019-05-28 2022-03-18 西莱克塔生物科技公司 Methods and compositions for attenuating an immune response against an antiviral transfer vector
US20200399628A1 (en) 2019-06-04 2020-12-24 Selecta Biosciences, Inc. Formulations and doses of pegylated uricase
CA3158408A1 (en) 2019-10-21 2021-04-29 Selecta Biosciences, Inc. Methods and compositions for treating liver diseases and disorders
AU2020380944A1 (en) 2019-11-08 2022-06-02 Selecta Biosciences, Inc. Formulations and doses of pegylated uricase
WO2021211100A1 (en) 2020-04-14 2021-10-21 Selecta Biosciences, Inc. Methods and compositions for inducing autophagy
US20210290601A1 (en) 2020-02-26 2021-09-23 Selecta Biosciences, Inc. Methods and compositions using synthetic nanocarriers comprising immunosuppressant
IL296326A (en) 2020-03-11 2022-11-01 Selecta Biosciences Inc Methods and compositions related to synthetic nanocarriers
EP4274571A1 (en) 2021-01-05 2023-11-15 Selecta Biosciences, Inc. Viral vector dosing protocols
KR20230167405A (en) 2021-04-09 2023-12-08 셀렉타 바이오사이언시즈, 인크. Synthetic nanocarriers containing immunosuppressants combined with high-affinity IL-2 receptor agonists to promote immune tolerance.
WO2022261148A1 (en) * 2021-06-09 2022-12-15 Scribe Therapeutics Inc. Compositions of glycoprotein particles
WO2023064367A1 (en) 2021-10-12 2023-04-20 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
CA3235269A1 (en) 2021-10-12 2023-04-20 Cartesian Therapeutics, Inc. Viral vector dosing protocols
WO2023086615A1 (en) 2021-11-14 2023-05-19 Selecta Biosciences, Inc. Multiple dosing with viral vectors
US20230263906A1 (en) 2022-01-10 2023-08-24 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing
US20230322884A1 (en) 2022-03-09 2023-10-12 Selecta Biosciences, Inc. Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing
WO2023172624A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
US20230372535A1 (en) 2022-03-25 2023-11-23 Selecta Biosciences, Inc. Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists and anti-igm agents
US20230381277A1 (en) 2022-04-08 2023-11-30 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4920016A (en) * 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US4937119A (en) * 1988-12-15 1990-06-26 Hoechst Celanese Corp. Textured organic optical data storage media and methods of preparation
US5516507A (en) * 1993-05-07 1996-05-14 L'oreal Dermatological glutathione alkyl ester composition and a process for topical treatment
US5736156A (en) * 1995-03-22 1998-04-07 The Ohio State University Liposomal anf micellular stabilization of camptothecin drugs
US5985832A (en) * 1996-12-20 1999-11-16 Board Of Regents, The University Of Texas System Compositions and methods of use for osteoclast inhibitor factors
US6033645A (en) * 1996-06-19 2000-03-07 Unger; Evan C. Methods for diagnostic imaging by regulating the administration rate of a contrast agent

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
DK143689C (en) * 1975-03-20 1982-03-15 J Kreuter PROCEDURE FOR THE PREPARATION OF AN ADVERTISED VACCINE
US4177177A (en) 1976-03-26 1979-12-04 El Aasser Mohamed S Polymer emulsification process
FR2504408B1 (en) 1981-04-24 1986-02-14 Couvreur Patrick PROCESS FOR THE PREPARATION OF SUBMICROSCOPIC PARTICLES, PARTICLES THUS OBTAINED AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
PT85521B (en) 1986-08-11 1990-06-29 Innovata Biomed Ltd METHOD FOR PREPARING PHARMACEUTICAL COMPOSITIONS CONTAINING MICROCAPSULES
FR2634397B2 (en) 1986-12-31 1991-04-19 Centre Nat Rech Scient PROCESS FOR THE PREPARATION OF DISPERSIBLE COLLOIDAL SYSTEMS OF A PROTEIN IN THE FORM OF NANOPARTICLES
EP0309527B1 (en) 1987-04-16 1993-01-20 Christian Bindschaedler Process for preparing a powder of water-insoluble polymer which can be redispersed in a liquid phase and process for preparing a dispersion of the powdered polymer
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
IL98744A0 (en) * 1990-07-06 1992-07-15 Gen Hospital Corp Method of studying biological tissue using monocrystalline particles
US5487390A (en) * 1990-10-05 1996-01-30 Massachusetts Institute Of Technology Gas-filled polymeric microbubbles for ultrasound imaging
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
GB9116610D0 (en) 1991-08-01 1991-09-18 Danbiosyst Uk Preparation of microparticles
US6113946A (en) 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
US6197346B1 (en) 1992-04-24 2001-03-06 Brown Universtiy Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
DE4223169C1 (en) 1992-07-10 1993-11-25 Ferring Arzneimittel Gmbh Process for the microencapsulation of water-soluble active substances
GB9300875D0 (en) * 1993-01-18 1993-03-10 Ucb Sa Nanocapsule containing pharmaceutical compositions
US5558855A (en) * 1993-01-25 1996-09-24 Sonus Pharmaceuticals Phase shift colloids as ultrasound contrast agents
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
JP3746293B2 (en) 1993-02-22 2006-02-15 アメリカン バイオサイエンス、インコーポレイテッド Methods for in vivo delivery of biologics and compositions therefor
DK0809110T3 (en) 1993-03-09 2004-05-24 Baxter Int Macromolecular microparticles and methods of preparation
WO1995003789A1 (en) 1993-07-28 1995-02-09 The Johns Hopkins University School Of Medicine Controlled release of pharmaceutically active substances from coacervate microcapsules
CA2136373A1 (en) * 1993-11-29 1995-05-30 Steven W. Medina Ethoxylated acetylenic glycols having low dynamic surface tension
DE4341114A1 (en) * 1993-12-02 1995-06-08 Ifac Gmbh Emulsions comprising non-aqueous phase dispersed in oil phase
US5962427A (en) 1994-02-18 1999-10-05 The Regent Of The University Of Michigan In vivo gene transfer methods for wound healing
FR2721510B1 (en) 1994-06-22 1996-07-26 Rhone Poulenc Rorer Sa Nanoparticles filterable under sterile conditions.
US5858398A (en) * 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
US5629021A (en) 1995-01-31 1997-05-13 Novavax, Inc. Micellar nanoparticles
US6165988A (en) 1995-02-10 2000-12-26 Christian Noe Medicament in particulate form
US6139819A (en) * 1995-06-07 2000-10-31 Imarx Pharmaceutical Corp. Targeted contrast agents for diagnostic and therapeutic use
US6051258A (en) 1995-06-07 2000-04-18 Emisphere Technologies, Inc. Proteinoid emulsions and methods for preparation and use thereof
DK0752245T3 (en) 1995-07-05 2002-09-09 Europ Economic Community Biocompatible and biodegradable nanoparticles developed for the absorption and delivery of proteinaceous drugs
WO1997003702A1 (en) 1995-07-21 1997-02-06 Brown University Research Foundation A method for gene therapy using nucleic acid loaded polymeric microparticles
US6143211A (en) 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
JPH11514348A (en) * 1995-09-08 1999-12-07 ベス イスラエル ディーコネス メディカル センター Isolation of microdomains of caveole and GPI anchor proteins
KR0180334B1 (en) * 1995-09-21 1999-03-20 김윤 Drug messenger using el-2l-2 micelle and method for sealing drug to it
US5648097A (en) 1995-10-04 1997-07-15 Biotek, Inc. Calcium mineral-based microparticles and method for the production thereof
FR2742357B1 (en) 1995-12-19 1998-01-09 Rhone Poulenc Rorer Sa STABILIZED AND FILTRABLE NANOPARTICLES UNDER STERILE CONDITIONS
DE19605279A1 (en) 1996-02-13 1997-08-14 Hoechst Ag Target cell-specific vectors for the introduction of genes into cells, drugs containing such vectors and their use
KR100236771B1 (en) 1997-04-01 2000-02-01 성재갑 Hyaluronate microparticles for sustained release of drug
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6143037A (en) 1996-06-12 2000-11-07 The Regents Of The University Of Michigan Compositions and methods for coating medical devices
EP0910351A1 (en) * 1996-06-27 1999-04-28 G.D. Searle & Co. Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
FR2751222B1 (en) * 1996-07-16 1998-10-09 Capsulis COMPOSITIONS CONTAINING AT LEAST ONE NUCLEIC ACID AND THEIR APPLICATIONS IN THE BIOMEDICAL FIELD, PARTICULARLY IN GENE THERAPY
US6030956A (en) * 1996-10-24 2000-02-29 Boulikas; Teni Combination gene therapy for human cancers
US5874111A (en) 1997-01-07 1999-02-23 Maitra; Amarnath Process for the preparation of highly monodispersed polymeric hydrophilic nanoparticles
EP0860167A1 (en) 1997-01-30 1998-08-26 Robert Gurny RNA-and DNA- based active agents in nanoparticles
KR20000076157A (en) * 1997-03-11 2000-12-26 리전츠 오브 더 유니버스티 오브 미네소타 Dna-based transposon system for the introduction of nucleic acid into dna of a cell
ES2236891T3 (en) * 1997-03-12 2005-07-16 Abbott Laboratories HYDROFILE BINARY SYSTEMS FOR THE ADMINISTRATION OF CYCLOSPORINE.
AU6229498A (en) * 1997-04-07 1998-10-30 Daiichi Pharmaceutical Co., Ltd. Composition for gene introduction into cell
DE19723308A1 (en) * 1997-06-04 1998-12-10 Wolfgang A Prof Dr Wohlrab Microemulsions useful for topical administration of e.g. local anaesthetics
CN100462066C (en) 1997-06-27 2009-02-18 美国生物科学有限公司 Novel formulations of pharmacological agents, method for preparation thereof and method for use thereof
US6165440A (en) 1997-07-09 2000-12-26 Board Of Regents, The University Of Texas System Radiation and nanoparticles for enhancement of drug delivery in solid tumors
MY131805A (en) * 1997-09-18 2007-09-28 Biogen Idec Inc Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis.
AU5860798A (en) 1997-12-29 1999-07-19 Universite De Geneve Method for producing an aqueous colloidal dispersion of nanoparticles
IT1298575B1 (en) * 1998-02-06 2000-01-12 Vectorpharma Int PHARMACEUTICAL COMPOSITIONS IN THE FORM OF NANOPARTICLES INCLUDING LIPID SUBSTANCES AND ANTIPHILIC SUBSTANCES AND RELATED PROCESS OF
CA2335472C (en) 1998-06-19 2008-10-28 Rtp Pharma Inc. Processes to generate submicron particles of water-insoluble compounds
JP5296954B2 (en) * 1998-11-20 2013-09-25 オバン・エナジー・リミテッド Method for producing a stable suspension of insoluble particulates
JP2002536386A (en) 1999-02-12 2002-10-29 コラジェネシス インク． Collagen-based injection system for delivery of cells or therapeutic agents
CA2400172C (en) * 2000-02-28 2010-04-20 Genesegues, Inc. Nanocapsule encapsulation system and method
US20040038303A1 (en) * 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
WO2006065724A2 (en) * 2004-12-14 2006-06-22 Regents Of The University Of Minnesota Casein kinase 2 antisense therapy
US20090238883A1 (en) * 2006-04-28 2009-09-24 Kren Betsy T Liver-specific nanocapsules and methods of using

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4920016A (en) * 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US4937119A (en) * 1988-12-15 1990-06-26 Hoechst Celanese Corp. Textured organic optical data storage media and methods of preparation
US5516507A (en) * 1993-05-07 1996-05-14 L'oreal Dermatological glutathione alkyl ester composition and a process for topical treatment
US5736156A (en) * 1995-03-22 1998-04-07 The Ohio State University Liposomal anf micellular stabilization of camptothecin drugs
US6033645A (en) * 1996-06-19 2000-03-07 Unger; Evan C. Methods for diagnostic imaging by regulating the administration rate of a contrast agent
US5985832A (en) * 1996-12-20 1999-11-16 Board Of Regents, The University Of Texas System Compositions and methods of use for osteoclast inhibitor factors

Also Published As

Publication number Publication date
WO2001064164A2 (en) 2001-09-07
US6632671B2 (en) 2003-10-14
JP4751556B2 (en) 2011-08-17
US20030170893A1 (en) 2003-09-11
CA2400172A1 (en) 2001-09-07
MXPA02008361A (en) 2004-05-17
JP2003524654A (en) 2003-08-19
HK1048772A1 (en) 2003-04-17
CN1406140A (en) 2003-03-26
AU2001247244B2 (en) 2005-06-02
US20040137071A1 (en) 2004-07-15
EP1267946A4 (en) 2008-07-02
AU4724401A (en) 2001-09-12
EP1267946A2 (en) 2003-01-02
CA2400172C (en) 2010-04-20

Similar Documents

Publication Publication Date Title
WO2001064164A3 (en) Nanocapsule encapsulation system and method
CA2357032A1 (en) Method for the preparation of starch particles
ATE173652T1 (en) METHOD FOR PRODUCING MICRO CAPSULES
CA2184842A1 (en) New stabilized galenic formulations comprising an acid labile benzimidazole compound and its preparation
WO1998029535A3 (en) Nanoscale particles synthesized within an assembled virion
WO2002064245A3 (en) Preparation of particles by hydrolyzing a metal cation in the presence of a polymer, resulting particles and uses thereof
CA2388344A1 (en) Amphiphilic polymeric vesicles
ATE263623T1 (en) LOW VISCOSE, FORMALDEHYDE REDUCED DISPERSIONS OF MICROCAPSULES MADE OF MELAMINE-FORMALDEHYDE RESINS
WO2002015927A8 (en) High mannose proteins and methods of making high mannose proteins
WO2003092043A3 (en) Luminescent nanoparticles and methods for their preparation
WO2003022650A8 (en) Method for stabilizing the driving state of a utility vehicle combination
CA2377566A1 (en) Low spray force, low retention atomization system
WO2005021638A3 (en) Aqueous dispersion, its production method, and its use
CA2405716A1 (en) Chemically modified novel erythropoietin stimulating protein compositions and methods
FR2766368B1 (en) METHOD FOR PREPARING NANOCAPSULES OF THE VESICULAR TYPE, USABLE IN PARTICULAR AS COLLOIDAL VECTORS OF PHARMACEUTICAL OR OTHER ACTIVE PRINCIPLES
EP1002810A4 (en) Polymer emulsion and process for producing the same
CA2017676A1 (en) Method for making absorbent starch
WO1997046264A3 (en) Pressure resistant protein microspheres as ultrasonic imaging agents
CA2275929A1 (en) Aqueous suspension composition and water-dispersible dry composition
EP0850979A3 (en) Method of manufacturing cellulose beads.
CN111908478A (en) Preparation method of flexible silica aerogel
EP1135001A3 (en) Apparatus and method for automatic port identity discovery in hierarchical heterogenous systems
CA2450235A1 (en) Aqueous composition
EP1162955B1 (en) Nanoparticles, complexes with polynucleotides and their use
EP1086973A3 (en) Polyimide gas separation membranes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2400172

Country of ref document: CA

Ref document number: 2001920161

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/01093/MU

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2001247244

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2001 563063

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/008361

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 018057926

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2001920161

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2001247244

Country of ref document: AU